search
Back to results

Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder

Primary Purpose

Major Depressive Disorder

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Vortioxetine 10 mg
Paroxetine 20 mg
Placebo
Sponsored by
H. Lundbeck A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Major Depressive Disorder

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • The patient has MDD, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR™) recurrent major depressive disorder (MDD) (classification 296.3x).
  • The patient has a MADRS total score ≥26.
  • The patient has had the current major depressive episode (MDE) for ≥3 months.
  • The patient is aged ≥18 and ≤65 years.
  • The patient is employed full or part-time (defined as minimum 50% full time working hours per week). Part time work should not be due to a medical or mental illness other than MDD.
  • The patient has been in the current job/position for at least 3 months.
  • The patient has no plans to change jobs or retire within treatment period.
  • The patient is not on a sick leave, and at the Screening and Randomisation Visits, there are no plans to send the patient on a sick leave.
  • The patient is not receiving disability benefits.

Exclusion criteria:

  • The patient has a score ≥70 on the DSST (number of correct symbols) at the Baseline Visit.
  • The patient is, in the opinion of the investigator, not able to complete the neuropsychological tests validly at the Baseline Visit.
  • The patient has physical, cognitive, or language impairment of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
  • The patient is diagnosed with reading disability (dyslexia).
  • The patient has a history of lack of response to previous adequate treatment with vortioxetine or paroxetine.
  • The patient has any current psychiatric disorder or Axis I disorder (according to DSM-IV-TR™ criteria) other than MDD, as assessed using MINI.
  • The patient has a current or has had a diagnosis of dysthymic disorder within 3 months preceding the onset of current episode (DSM-IV-TR™ criteria).
  • The patient has borderline, schizotypal, schizoid, paranoid, or histrionic, antisocial personality disorders (axis II) as comorbid or primary diagnosis (DSM-IV-TR™ criteria).
  • The patient suffers from personality disorders, mental retardation, pervasive development disorder, attention-deficit/hyperactivity disorder, organic mental disorders, or mental disorders due to a general medical condition (DSM-IV-TR™ criteria).
  • The patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features (DSM-IV-TR™ criteria).

Other protocol-defined inclusion and exclusion criteria may apply.

Sites / Locations

  • EE001
  • EE002
  • EE004
  • FI002
  • FI003
  • FI001
  • FI008
  • FI007
  • DE002
  • DE001
  • DE003
  • DE007
  • DE008
  • LT002
  • LT006
  • LT003
  • LT001
  • LT005

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Other

Placebo Comparator

Arm Label

Vortioxetine 10 mg

Paroxetine 20 mg (active reference)

Placebo

Arm Description

daily, encapsulated, orally

daily, encapsulated, orally

capsules, orally

Outcomes

Primary Outcome Measures

Change in Digit Symbol Substitution Test (DSST): number of correct symbols

Secondary Outcome Measures

Change in Trail Making Test (TMT) score: TMT-A; speed of processing
Change in TMT-B; executive functioning
Change in reaction time score: Choice Reaction Time (CRT); attention
Change in reaction time score: Simple Reaction Time (SRT); psychomotor speed)
Change in Stroop Colour Naming Test (STROOP): incongruent score; executive functioning
Change in STROOP: congruent score; speed of processing
Change in Perceived Deficits Questionnaire - Depression (PDQ-D) total score
Change in Montgomery and Asberg Depression Rating Scale (MADRS) total score
Change in Clinical Global Impression - Severity of Illness (CGI-S)
Clinical Global Impression - Global Improvement (CGI-I) score
Change in the Functioning Assessment Short Test (FAST) total score
Change in University of San Diego Performance-based Skills Assessment - Brief (UPSA-B) total score

Full Information

First Posted
October 21, 2014
Last Updated
February 27, 2017
Sponsor
H. Lundbeck A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT02279966
Brief Title
Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder
Official Title
An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-referenced (Paroxetine), Fixed-dose Study on the Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
October 2014 (Actual)
Primary Completion Date
February 2016 (Actual)
Study Completion Date
February 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
H. Lundbeck A/S

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To assess the efficacy of acute treatment with 10 mg/day vortioxetine versus placebo on cognitive performance (focusing on the aspect concerning speed of processing, executive functioning, attention) in working patients with major depressive disorder (MDD).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Depressive Disorder

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
152 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Vortioxetine 10 mg
Arm Type
Experimental
Arm Description
daily, encapsulated, orally
Arm Title
Paroxetine 20 mg (active reference)
Arm Type
Other
Arm Description
daily, encapsulated, orally
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
capsules, orally
Intervention Type
Drug
Intervention Name(s)
Vortioxetine 10 mg
Other Intervention Name(s)
Brintellix®, Lu AA21004
Intervention Type
Drug
Intervention Name(s)
Paroxetine 20 mg
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Change in Digit Symbol Substitution Test (DSST): number of correct symbols
Time Frame
Baseline to Week 8
Secondary Outcome Measure Information:
Title
Change in Trail Making Test (TMT) score: TMT-A; speed of processing
Time Frame
Baseline to Week 8
Title
Change in TMT-B; executive functioning
Time Frame
Baseline to Week 8
Title
Change in reaction time score: Choice Reaction Time (CRT); attention
Time Frame
Baseline to Week 8
Title
Change in reaction time score: Simple Reaction Time (SRT); psychomotor speed)
Time Frame
Baseline to Week 8
Title
Change in Stroop Colour Naming Test (STROOP): incongruent score; executive functioning
Time Frame
Baseline to Week 8
Title
Change in STROOP: congruent score; speed of processing
Time Frame
Baseline to Week 8
Title
Change in Perceived Deficits Questionnaire - Depression (PDQ-D) total score
Time Frame
Baseline to Week 8
Title
Change in Montgomery and Asberg Depression Rating Scale (MADRS) total score
Time Frame
Baseline to Week 8
Title
Change in Clinical Global Impression - Severity of Illness (CGI-S)
Time Frame
Baseline to Week 8
Title
Clinical Global Impression - Global Improvement (CGI-I) score
Time Frame
Week 8
Title
Change in the Functioning Assessment Short Test (FAST) total score
Time Frame
Baseline to Week 8
Title
Change in University of San Diego Performance-based Skills Assessment - Brief (UPSA-B) total score
Time Frame
Baseline to Week 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The patient has MDD, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR™) recurrent major depressive disorder (MDD) (classification 296.3x). The patient has a MADRS total score ≥26. The patient has had the current major depressive episode (MDE) for ≥3 months. The patient is aged ≥18 and ≤65 years. The patient is employed full or part-time (defined as minimum 50% full time working hours per week). Part time work should not be due to a medical or mental illness other than MDD. The patient has been in the current job/position for at least 3 months. The patient has no plans to change jobs or retire within treatment period. The patient is not on a sick leave, and at the Screening and Randomisation Visits, there are no plans to send the patient on a sick leave. The patient is not receiving disability benefits. Exclusion criteria: The patient has a score ≥70 on the DSST (number of correct symbols) at the Baseline Visit. The patient is, in the opinion of the investigator, not able to complete the neuropsychological tests validly at the Baseline Visit. The patient has physical, cognitive, or language impairment of such severity as to adversely affect the validity of the data derived from the neuropsychological tests. The patient is diagnosed with reading disability (dyslexia). The patient has a history of lack of response to previous adequate treatment with vortioxetine or paroxetine. The patient has any current psychiatric disorder or Axis I disorder (according to DSM-IV-TR™ criteria) other than MDD, as assessed using MINI. The patient has a current or has had a diagnosis of dysthymic disorder within 3 months preceding the onset of current episode (DSM-IV-TR™ criteria). The patient has borderline, schizotypal, schizoid, paranoid, or histrionic, antisocial personality disorders (axis II) as comorbid or primary diagnosis (DSM-IV-TR™ criteria). The patient suffers from personality disorders, mental retardation, pervasive development disorder, attention-deficit/hyperactivity disorder, organic mental disorders, or mental disorders due to a general medical condition (DSM-IV-TR™ criteria). The patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features (DSM-IV-TR™ criteria). Other protocol-defined inclusion and exclusion criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Email contact via H. Lundbeck A/S
Organizational Affiliation
LundbeckClinicalTrials@lundbeck.com
Official's Role
Study Director
Facility Information:
Facility Name
EE001
City
Tallinn
Country
Estonia
Facility Name
EE002
City
Tallinn
Country
Estonia
Facility Name
EE004
City
Voru
Country
Estonia
Facility Name
FI002
City
Helsinki
Country
Finland
Facility Name
FI003
City
Helsinki
Country
Finland
Facility Name
FI001
City
Kuopio
Country
Finland
Facility Name
FI008
City
Oulu
Country
Finland
Facility Name
FI007
City
Tampere
Country
Finland
Facility Name
DE002
City
Berlin
Country
Germany
Facility Name
DE001
City
Bielefeld
Country
Germany
Facility Name
DE003
City
Frankfurt
Country
Germany
Facility Name
DE007
City
Frankfurt
Country
Germany
Facility Name
DE008
City
Schwerin
Country
Germany
Facility Name
LT002
City
Kaunas
Country
Lithuania
Facility Name
LT006
City
Palanga
Country
Lithuania
Facility Name
LT003
City
Silute
Country
Lithuania
Facility Name
LT001
City
Vilnius
Country
Lithuania
Facility Name
LT005
City
Vilnius
Country
Lithuania

12. IPD Sharing Statement

Citations:
PubMed Identifier
30439678
Citation
Christensen MC, Sluth LB, McIntyre RS. Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: Replication and extension of initial findings. J Affect Disord. 2019 Feb 15;245:508-516. doi: 10.1016/j.jad.2018.11.034. Epub 2018 Nov 5.
Results Reference
derived
Links:
URL
https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000230-34/results
Description
EMA EudraCT Results: 2014-000230-34

Learn more about this trial

Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder

We'll reach out to this number within 24 hrs